Evidence map›Paper›PMID 41798681›Full record

ArticleNeuro-oncology advances

Yutaro Takayama, Mariko Yaegashi, Kaishi Satomi, Takahiro Ishiyama, Masao Shioda, Osamu Yazawa, WeiKai Ye, Hinako Okagawa, Shuna Saito, Kanoko Sasaoka and 10 more

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yutaro TakayamaDepartment of Neurosurgery, Yokohama City University, Graduate School of Medicine, Yokohama.
Mariko YaegashiDepartment of Neurosurgery, Yokohama City University, Graduate School of Medicine, Yokohama.
Kaishi SatomiDepartment of Pathology, Kyorin University Faculty of Medicine, Tokyo.
Takahiro IshiyamaDepartment of Molecular Pathology, Yokohama City University, Graduate School of Medicine, Yokohama.
Masao ShiodaDepartment of Neurosurgery, Yokohama City University, Graduate School of Medicine, Yokohama.
Osamu YazawaDepartment of Neurosurgery, Yokohama City University, Graduate School of Medicine, Yokohama.
WeiKai YeLaboratory of Biopharmaceutical and Regenerative Science, Graduate School of Medical Science, Yokohama City University, Yokohama.
Hinako OkagawaLaboratory of Biopharmaceutical and Regenerative Science, Graduate School of Medical Science, Yokohama City University, Yokohama.
Shuna SaitoLaboratory of Biopharmaceutical and Regenerative Science, Graduate School of Medical Science, Yokohama City University, Yokohama.
Kanoko SasaokaDepartment of Neurosurgery, Yokohama City University, Graduate School of Medicine, Yokohama.
Miyu OkuraLaboratory of Biopharmaceutical and Regenerative Science, Graduate School of Medical Science, Yokohama City University, Yokohama.
Akihide KoyamaDepartment of Legal Medicine, Graduate School of Medical and Dental Science, Niigata University, Niigata.
Akito OshimaDepartment of Neurosurgery, Yokohama City University, Graduate School of Medicine, Yokohama.
Masaki SonodaDepartment of Neurosurgery, Yokohama City University, Graduate School of Medicine, Yokohama.
Manabu NatsumedaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata.ORCID https://orcid.org/0000-0003-3098-8323
Koichi IchimuraDepartment of Pathology, Kyorin University Faculty of Medicine, Tokyo.
Shoji YamanakaDepartment of Diagnostic Pathology, Yokohama City University Hospital, Yokohama.
Satoshi FujiiDepartment of Molecular Pathology, Yokohama City University, Graduate School of Medicine, Yokohama.
Tetsuya YamamotoDepartment of Neurosurgery, Yokohama City University, Graduate School of Medicine, Yokohama.
Kensuke TateishiDepartment of Neurosurgery, Yokohama City University, Graduate School of Medicine, Yokohama.ORCID https://orcid.org/0000-0001-6895-9013

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: High-grade glioma with pleomorphic and pseudopapillary features (HPAP) is a recently recognized glioma subtype defined by DNA methylation profiling. While it exhibits overlapping histological features with various CNS tumors, such as polymorphous low-grade neuroepithelial tumor of the young (PLNTY) and pleomorphic xanthoastrocytoma, its molecular pathogenesis and clinical behavior remain incompletely understood. Case Presentation: We report a rare case of HPAP with BRAF p.V600E mutation and PLNTY-like histological features that showed rapid tumor progression during long-term follow-up. A 47-year-old woman harbored a lesion that remained asymptomatic and slow-growing for over 20 years, but later exhibited contrast enhancement and rapid expansion. Partial tumor resection was performed with hippocampal preservation based on intraoperative genetic testing and functional considerations. No regrowth of the residual hippocampal lesion was observed at 12 months postoperatively. Histologically, the tumor showed oligodendroglioma-like morphology, strong CD34 immunopositivity, consistent with PLNTY-like features, but indicated a high proliferative index. Molecular analysis revealed co-occurring BRAF p.V600E and TERT promoter (pTERT, c.-124C>T) mutations, with a lower variant allele frequency for the pTERT mutation. This disparity, confirmed by droplet digital PCR, suggests that the BRAF p.V600E mutation was an early, clonal event, whereas the pTERT mutation likely arose later in a subclonal population. DNA methylation profiling classified the tumor as HPAP with high confidence (NCI-Bethesda score: 0.969), and uniform manifold approximation and projection showed clustering within HPAP reference cases. Conclusion: This case represents a rare example of BRAF p.V600E-mutant HPAP with PLNTY-like features in which a subclonal pTERT mutation likely emerged during tumor evolution, contributing to rapid tumor progression. The combination of a prolonged indolent phase followed by rapid growth, along with the intratumoral genetic heterogeneity observed, provides novel insights into the biological diversity and evolutionary dynamics of HPAP.

Indexed as

BRAFDNA methylation classifierHPAPPLNTYTERT

Identifiers

PMID41798681
PMCPMC12962799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.